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Abstract 
Background: Control in COPD is a dynamic concept that can reflect changes in patients’ clinical status that may have 
prognostic implications, but there is no information about changes in control status and its long‑term consequences.
Methods: We classified 798 patients with COPD from the CHAIN cohort as controlled/uncontrolled at baseline and 
over 5 years. We describe the changes in control status in patients over long‑term follow‑up and analyze the factors 
that were associated with longitudinal control patterns and related survival using the Cox hazard analysis.
Results: 134 patients (16.8%) were considered persistently controlled, 248 (31.1%) persistently uncontrolled and 416 
(52.1%) changed control status during follow‑up. The variables significantly associated with persistent control were 
not requiring triple therapy at baseline and having a better quality of life. Annual changes in outcomes (health status, 
psychological status, airflow limitation) did not differ in patients, regardless of clinical control status. All‑cause mortal‑
ity was lower in persistently controlled patients (5.5% versus 19.1%, p = 0.001). The hazard ratio for all‑cause mortality 
was 2.274 (95% CI 1.394–3.708; p = 0.001). Regarding pharmacological treatment, triple inhaled therapy was the most 
common option in persistently uncontrolled patients (72.2%). Patients with persistent disease control more frequently 
used bronchodilators for monotherapy (53%) at recruitment, although by the end of the follow‑up period, 20% had 
scaled up their treatment, with triple therapy being the most frequent therapeutic pattern.
Conclusions: The evaluation of COPD control status provides relevant prognostic information on survival. There 
is important variability in clinical control status and only a small proportion of the patients had persistently good 
control. Changes in the treatment pattern may be relevant in the longitudinal pattern of COPD clinical control. Further 
studies in other populations should validate our results.
Trial registration: Clinical Trials.gov: identifier NCT01122758.
Keywords: Chronic obstructive pulmonary disease, Control, Management
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Over the last decade, we have seen new evidence that 
has led to a new vision of chronic obstructive pul-
monary disease (COPD) with the recognition of the 
multidimensional component and the concept of phe-
notype, which has meant a step forward on the road to 
personalized medicine and individualization of treatment 
[1–3].
Clinical practice guidelines in COPD establish the 
reduction of symptoms and minimization of risk as the 
main therapeutic objectives [4, 5]. These objectives make 
it necessary to adapt actions to the changes experienced 
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by patients throughout their evolution, considering ther-
apeutic success to mean achieving disease control.
The concept of COPD control is a new dimension 
that is proposed as a tool to help make therapeutic deci-
sions and to modulate treatment [6, 7]. According to 
this proposal, control is defined as a state of low clinical 
impact and an absence of exacerbations maintained over 
time. The prespecified criteria for clinical control were 
described by Soler Cataluña [6] and have subsequently 
been evaluated in several studies [8–10].
Control in COPD is a dynamic concept that can reflect 
changes in patients’ clinical status that may have prog-
nostic implications. Some studies have observed a poten-
tial predictive value for poor outcomes and previous 
studies have shown that improvement in control status 
in the short term was associated with better outcomes, 
improvement in health status, less frequent exacerba-
tions [11] and a longer delay until hospitalization [8]. 
However, this new concept requires validation in terms of 
its ability to predict outcomes and to provide additional 
clinical management insight. Given the limited infor-
mation about the changes in clinical control in patients 
with COPD and the relationship with outcomes in those 
patients, we assessed clinical control at baseline and lon-
gitudinally (annually over 5 years) in patients participat-
ing in the CHAIN (COPD History Assessment in Spain) 
cohort, aiming to use CHAIN data to explore the changes 
and consequences of clinical control in a large cohort of 
patients with COPD.
We hypothesized that worse persistent control would 
relate to worse clinical outcomes. We followed longitu-
dinal changes in physiological outcomes and patient-
reported outcomes for health status, dyspnea and 
psychological status over 5 years in patients with COPD. 
The objectives of the present study were as follows: (1) to 
evaluate the degree of control in patients with COPD; (2) 
to provide information on the longitudinal evolution of 
clinical control and to determine the factors associated 
with worse control; (3) to validate the concept of control 
as a predictor of the risk of poor outcomes.
Methods
The CHAIN methodology has been extensively reported 
previously [12]. Briefly, CHAIN is a Spanish multicenter 
study carried out at pulmonary clinics. The main goal of 
this prospective observational study was to multidimen-
sionally evaluate the progression of patients with COPD 
to better define the natural history and phenotypes of 
the disease. The recruitment period began on January 
15, 2010, and is ongoing (Clinical Trials.gov: identifier 
NCT01122758). All participants signed the informed 
consent approved by the ethics committees of the par-
ticipating centers (Hospital Universitario la Candelaria, 
Tenerife; Spain; IRB No. 258/2009). COPD was defined 
as a smoking history of at least 10 pack-years and an 
FEV1/FVC ratio less than 0.70 after inhaling 400  mg of 
albuterol. Patients were stable for at least 6  weeks and 
received optimal medical therapy. Exclusion criteria were 
uncontrolled comorbidities such as malignancy or other 
confounding diseases that could interfere with the study. 
The follow-up of the subjects included annual office vis-
its and a telephone call was scheduled every 6 months to 
compile data about the number of exacerbations, clinical 
impact (health-related quality of life, subjective percep-
tion) and to verify the subject’s vital status. COPD treat-
ment followed national [5] and international guidelines. 
Data analyzed in the present study was obtained from 
the recruitment date through September 2018. Data was 
anonymized with hierarchical access control in order to 
guarantee that information was secure.
Clinical and physiological measurements
Trained staff obtained information on age, sex, body 
mass index (BMI) and smoking status at baseline and 
subsequent visits. Comorbidities were scored using the 
Charlson index [13]. Pulmonary function tests were per-
formed according to international criteria [14, 15]. Dysp-
nea was evaluated using the modified Medical Research 
Council (mMRC) scale [16]. To evaluate health-related 
quality of life, the Spanish validated version of the COPD 
Assessment Test was used, which was self-administered 
by each patient under the supervision of the interviewer 
[17]. Anxiety and depression were evaluated using the 
Hospital Anxiety and Depression Scale (HAD) question-
naire [18]. Exacerbations were defined as a worsening of 
respiratory symptoms (dyspnea, cough or sputum) that 
required the use of antibiotics, systemic corticosteroids, 
or both, or symptoms that necessitated an emergency 
room visit or hospital admission. All-cause mortality was 
recorded using information obtained from the family and 
then confirmed by reviewing the medical record.
Clinical control status assessment
Control status was evaluated based on low clinical impact 
and stability, according to clinical criteria. A patient was 
considered controlled when disease was clinically sta-
ble and had low clinical impact, adjusted for the level of 
disease severity. Stability was defined as the absence of 
exacerbations in the previous 6  months plus no change 
or improvement in subjective perception referred to by 
the patient. Clinical impact was classified as low accord-
ing to the information collected on the dyspnea (mMRC) 
scale (0–1 if FEV1 ≥ 50% and 0–2 if FEV1 < 50%) and res-
cue medication usage (not needing to use rescue inhalers 
regularly). The level of control was evaluated longitudi-
nally during visits every 6  months. All participants had 
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a minimum of 12 months of follow-up with clinical con-
trol measurements. Based on the clinical control status 
evaluated at each visit during follow-up, the cohort was 
divided into three subgroups: persistently controlled, 
intermittently controlled and persistently uncontrolled 
patients.
Statistical analysis
Data is summarized as frequencies for categorical vari-
ables, median (5th–95th percentile) for ordinal or non-
normal scale variables and mean ± SD for normally 
distributed scale variables. Comparisons were made 
between groups using Pearson’s chi-squared test, the 
Kruskal–Wallis H test or the Mann–Whitney U test and 
one-way ANOVA or the t-test as appropriate.
Logistic regression was used to investigate factors con-
tributing to clinical control in patients with COPD. A 
multivariate analysis considered variables with a statisti-
cally significant association (p < 0.05). In the multivariate 
model, we considered the following independent vari-
ables: age, pack-years, chronic bronchitis, dark sputum, 
eosinophils, Charlson index, FEV1, KCO, triple therapy, 
CAT score and HDAS depression.
We chose the best predictive model, which only had 
the variables CAT score and triple therapy because the 
others weren’t as relevant to provide a good model. To 
select the model, we used the Akaike and Bayesian infor-
mation criteria. The final set of variables was selected 
using a backward stepwise selection algorithm (p < 0.10 
to remain in the model). The discrimination capacity 
of the predictive model was analyzed by calculating the 
area under the Receiver Operating Characteristics (ROC) 
curve along with a confidence interval at 95%.
An unpaired t -test was used to compare baseline data 
and annual changes between persistently controlled and 
persistently uncontrolled status. P values less than 0.05 
were considered to be statistically significant.
A Kaplan–Meier analysis for survival due to all causes 
was performed in persistently uncontrolled patients. 
Finally, to predict the risk of death, we performed Cox 
proportional hazard regression analyses with the persis-
tently controlled and uncontrolled subgroups. Signifi-
cance was established as two-tailed p < 0.05.
Results
Participant characteristics
The population of this study was 798 patients with COPD 
from the CHAIN study who underwent a minimum of 
12  months of follow-up with clinical control measure-
ments. Stability was defined as the absence of exacerba-
tions in the last 12 months during the recruitment visit. 
A total of 264 (33%) patients met the criteria for con-
trolled status at recruitment. A comparison of controlled 
versus uncontrolled patient characteristics is presented 
in Table  1. Uncontrolled patients were older and had a 
higher body mass index and greater degree of airflow lim-
itation, with more chronic bronchitis and the presence of 
dark sputum, more comorbidities and a poor quality of 
life. Regarding pharmacological treatment, uncontrolled 
patients more frequently used inhaled triple therapy.
Control status according to degree of airflow limitation 
at recruitment
Of a total of 300 patients with severe/very severe airflow 
limitation, 228 patients (76%) were defined as having low-
impact disease and 100 patients (33.3%) had stable dis-
ease; therefore, 26.7% were defined as controlled patients. 
In mild/moderate COPD, there was a greater proportion 
of patients with stable disease: 262 patients (52.6%). Of 
these, 36.9% patients were defined as controlled (Table 2).
Prevalence and longitudinal follow‑up of clinical control
Over a period of 5  years, the proportion of persistently 
controlled patients with COPD was 16.8%, persistently 
uncontrolled patients accounted for 31.1% and inter-
mittently controlled patients represented 52.1% (Fig.  1). 
There were significant differences in baseline clinical and 
physiological characteristics between the persistently 
controlled patients with COPD compared to those who 
were persistently uncontrolled or intermittently con-
trolled (Table 3).
During this follow-up over 5 years, the median follow-
up time in the persistently controlled patient group was 
2.4 (1.7) years, 4.2 (1.2) years in the intermittently con-
trolled group and 1.8 (1.3) years for persistently uncon-
trolled patients. The loss of patients during follow-up was 
35.7%.
Factors accounting for persistently controlled patient status
A backward logistic multivariate model was developed 
with persistent control as the independent variable and 
the dependent variables were clinical and demographic 
variables, which were not related to the definition of 
control. The adjusted model showed that triple therapy 
(OR, 0.3026; 95% CI, 0.1776–0.51573; p < 0.001) and 
CAT (OR, 0.9399; 95% CI 0.9032–0.9781; p < 0.001) were 
independently and significantly associated with persis-
tently controlled status. The AUC was 0.7029 (95% CI, 
0.64209–0.76367).
Changes in treatment patterns for COPD in persistently 
controlled and uncontrolled patients
Regarding pharmacological treatment, persistently 
uncontrolled patients more frequently used inhaled 
corticosteroids, particularly as part of triple ther-
apy (72.2%). Of these, 71.8% showed no changes in 
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treatment during follow-up, 13.3% underwent de-
escalation and 14.9% escalation in treatment. Patients 
who were persistently controlled more frequently used 
bronchodilators, particularly monotherapy (53%), fol-
lowed by triple therapy (37%). Of these, 5.2% de-esca-
lated treatment and 19.4% scaled up their treatment, 
with triple therapy being the most frequent therapeutic 
pattern (Fig. 2).
Outcomes in patients with COPD according to longitudinal 
control status pattern
Longitudinal changes in clinical outcomes (health status, 
psychological status and airflow limitation) according 
to a persistently uncontrolled or controlled longitudinal 
control status pattern are shown in Table 4.
Regarding the baseline data, persistently uncontrolled 
patients were significantly worse as rated by CAT and 
HDAS scores and FEV1 levels. However, there were 
no significant differences in annual changes in out-
comes between persistently controlled and uncontrolled 
patients.
Regarding survival, there were 94 (24.6%) deaths in 382 
patients with a persistently uncontrolled or controlled 
status pattern, of which 73 (19.1%) were persistently 
uncontrolled and 21 (5.5%) were persistently controlled 
(p = 0.001). The Kaplan–Meier analysis for all-cause 
mortality showed that persistently uncontrolled status 
was associated with a shorter survival time (3.58  years; 
95% CI, 3.31–3.85) than persistently controlled status 
Table 1 Characteristics of the study population according to control status at recruitment
BMI body mass index, FEV1 forced expiratory volume in 1 s, KCO carbon monoxide transfer coefficient, Inhaled triple therapy: long-acting beta-2 agonist (LAMA) 





n = 264 (33%)
Uncontrolled n = 534 
(66.8%)
P-value
Age (years), m (SD) 65.7 (10.5) 62.8 (11.6) 67.2 (9.7) < 0.001
Gender (male), n (%) 663 (82.9) 226 (85.6) 435 (81.5) 0.144
Active smoker, n (%) 229 (28.6) 92 (34.8) 136 (25.5) 0.006
Tobacco exposure, pack‑years, m (SD) 56.3 (28.7) 52.6 (25.8) 58.2 (29.9) 0.018
BMI (kg/m2), m (SD) 28.0 (5.1) 27.2 (4.7) 28.4 (5.2) 0.001
Post‑bronchodilator FEV1 (%), m (SD) 60.2 (25.9) 68.0 (20.8) 56.4 (27.3) < 0.001
Post‑bronchodilator FEV1 (mL), m (SD) 1629.9 (690.4) 1944.0 (746.4) 1476.6 (602.7) < 0.001
KCO%, median (P25‑P75) 73 (51–92.9) 76.05 (60–95) 70 (46–91) 0.002
Chronic bronchitis, n (%) 466 (58.2) 132 (50.0) 334 (62.5) 0.001
Dark sputum, n (%) 122 (15.2) 29 (11.0) 93 (17.4) 0.018
Bronchial asthma, n (%) 26 (3.3) 11 (4.2) 15 (2.8) 0.309
Eosinophils (%), median (P25‑P75) 2.3 (1.5–3.6) 2.4 (1.6–3.6) 2.3 (1.5–3.6) 0.666
Charlson index, m (SD) 1.2 (1.5) 1.0 (1.5) 1.3 (1.5) 0.009
Treatment, n (%)
Inhaled triple therapy 454 (56.8) 105 (39.8) 348 (65.2)  < 0.001
Theophylline 73 (9.1) 8 (3.0) 65 (12.2)  < 0.001
Influenza vaccine 430 (53.7) 102 (38.6) 328 (61.4)  < 0.001
LTOT 104 (13.0) 9 (3.4) 95 (17.8)  < 0.001
Home ventilation 41 (5.1) 9 (3.4) 32 (6.0) 0.120
CAT score, m (SD) 12.6 (7.2) 10.3 (6.5) 13.8 (7.3)  < 0.001
Anxiety, HDAS, m (SD) 11.1 (4.8) 11.06 (4.8) 11.19 (4.9) 0.576
Depression, HDAS, m (SD) 8.6 (4.7) 8.2 (4.5) 8.9 (4.7) 0.088
Table 2 Factors accounting for  the  control status 
of patients with COPD by level of severity at recruitment








Clinical impact  < 0.001
Low, n (%) 546 (68.4) 318 (63.9) 228 (76.0)
High, n (%) 252 (31.6) 180 (36.1) 72 (24.0)
Stability
Stable, n (%) 362 (45.4) 262 (52.6) 100 (33.3)
Not stable, n (%) 436 (54.6) 236 (47.4) 200 (66.7)  < 0.001
Control status
Controlled, n (%) 264 (33.0) 184 (36.9) 80 (26.7)
Uncontrolled, n (%) 534 (67.0) 314 (63.1) 220 (73.3) 0.003
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(4.43 years; 95% CI, 4.19–4.67) (Fig. 3). The hazard ratio 
for all-cause mortality was 2.274 (95% CI, 1.394–3.708; 
p = 0.001).
Discussion
This study provides novel information on the longitudinal 
evolution of clinical control in a large cohort of patients 
with COPD as well as factors associated with persistent 
clinical control and their clinical consequences.
The main results of our study indicate three things. 
First, in the population with COPD, there were frequent 
changes in clinical control status. Only a small percent-
age of patients could be classified as persistently con-
trolled over the following 5  years. Secondly, the main 
variables associated with persistent clinical control are 
a better quality of life as evaluated by the CAT and not 
requiring inhaled triple therapy. Finally, the clinical con-
sequences of persistent clinical control are observed in 
the risk of death.
The current analysis describes the progression of clini-
cal control in a well-characterized COPD cohort over a 
period of 5  years as monitored at pulmonary clinics. In 
our study, only 33% of patients with different degrees of 
COPD severity met the criteria required to be consid-
ered controlled at recruitment. In the mild or moderate 
subgroup of patients, 36.9% were defined as controlled 
whereas only 26.7% of severe patients were defined as 
controlled. These results are similar to those obtained 
in an international multicenter study, obtaining an over-
all control value of 32% using the clinical evaluation of 
control criteria [10]. Another prospective study showed 
similar results, with only 27.5% [8] of patients being con-
sidered controlled. However, it should be mentioned that 
unlike these studies, almost 40% of the sample analyzed 
in our study had severe airflow obstruction. In addition, 
the level of physical activity referred to by the patient and 
the presence of sputum purulence were not included in 
the clinical impact assessment. In our study population, 
Fig. 1 The evolution of the clinical control pattern every year
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the use of rescue medication as a high impact criterion 
was present in 70% of patients classified as having a high 
clinical impact. This is a widely justified criterion if we 
fear that the increased use of rescue medication has been 
associated with an increased risk of future exacerbations 
[19]. However, sputum color has shown the lowest dis-
criminative property for the level of impact [10]. In our 
study, dark sputum was present in 11.2% of persistently 
controlled patients compared to 21.4% of persistently 
uncontrolled patients (p = 0.015).
Regarding the longitudinal clinical control patterns, we 
found that there were frequent changes in clinical con-
trol status, with 42.1% of patients changing control status 
during the observation period. Few studies have shown 
data on the progression of clinical control in COPD. A 
recent international study showed that 53.7% of patients 
Table 3 Baseline characteristics of longitudinal clinical control patterns
BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, KCO carbon monoxide transfer coefficient, Triple therapy long-acting beta-2 
agonist (LAMA) with corticosteroids (ICS) with long-acting antimuscarinic agent (LAMA), LTOT long-term oxygen therapy, CAT COPD Assessment Test, HDAS Hospital 
Anxiety and Depression Scale
a p < 0.001 persistently controlled compared with intermittently controlled
b p < 0.001 persistently controlled compared with persistently uncontrolled
c P ≤ 0.05 persistently uncontrolled compared with intermittently controlled
d P < 0.05 persistently controlled compared with persistently uncontrolled
e P ≤ 0.001 persistently uncontrolled compared with intermittently controlled








Demographics and clinical data
Male, n (%) 117 (87.3) 336 (80.6) 209 (84.3) 0.153
Age (years), m (SD) 63.2 (9.7)a,b 64.9 (10.9) 68.5 (9.9) < 0.001
Pack‑years, m (SD) 53.5 (26.1) 54.6 (28.4) 60.8 (30.2)c 0.013
Active smoker, n (%) 48 (35.8) 115 (27.6) 66 (26.6) 0.128
BMI (kg/m2), m (SD) 27.1 (4.6) 28.0 (4.8) 28.5 (5.6) 0.060
Chronic bronchitis, n (%) 71 (53.0)d 233 (55.9) 162 (65.3) 0.022
Dark sputum, n (%) 15 (11.2)d 54 (12.9) 53 (21.4)c 0.005
Bronquial asthma, n (%) 5 (3.7) 9 (2.2) 12 (4.8) 0.164
Eosinophils (%), median (P25‑P75) 2.6 (1.6–3.9)d 2.4 (1.6–3.6) 2.1 (1.3–3.3)c 0.002




2050 (1467–2505)b 1600 (1190–2050)a 1360 (940–1730)£  < 0.001
FEV1%pred,
median (P25‑P75)
72 (55–88)b 60 (46–74)a 51 (39–63)£  < 0.001
FVC (L),
median (P25‑P75)
3585 (2847–4380)b 3100 (2450‑ 3710)a 2745 (2197–3227)e  < 0.001
FVC %pred,
median (P25‑P75)
94 (80–110)b 84 (71–101)a 75 (63–90)e  < 0.001
FEV1/FVC,
median (P25‑P75)
58 (49–65)b 54 (44–63)f 51 (41–60)c  < 0.001
KCO%, median (P25‑P75) 79.5 (62.5–99.7)
b 72.6 (52.2–92.8)f 66 (41–85.2)c  < 0.001
Treatment
Triple therapy, n (%) 50 (37.3)b 226 (54.2)f 178 (71.8)e  < 0.001
Influenza vaccine, n (%) 50 (37.3)b 213 (51.1)f 167 (67.3)c  < 0.001
LTOT, n (%) 3 (2.2)b 37 (8.9) 64 (25.8)e  < 0.001
VMNI, n (%) 5 (3.7)b 12 (2.9) 24 (9.7)c  < 0.001
CAT score, median (P25‑P75) 8 (5–14.2)b,f 11 (7–16) 14 (9–21)e  < 0.001
HDAS anxiety score, median (P25‑P75) 11 (6–15) 12 (8–15) 12 (8–15) 0.576
HDAS depression score, median (P25‑P75) 8.0 (4.6) 8.5 (4.5) 9.3 (4.9) 0.048
Follow‑up time (years), m (SD) 2.4 (1.7) d 4.2 (1.2)a 1.8 (1.3)e  < 0.001
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changed control status, 29.8% of patients remained con-
trolled and 16% persistently uncontrolled during an 
18-month follow-up [20]. These results are not compara-
ble to our analysis, where follow-up is greater. Another 
observational study analyzed changes in control over a 
3-month period and showed that 29.2% changed their 
control status [11]. In this study, these changes were sig-
nificantly more frequent than changes in GOLD stage, 
risk level or in phenotype, which further suggests that 
control status could be used as a supplementary assess-
ment tool for decision-making at each medical visit, 
similar to the evaluation of asthma control. Table 5 sum-
marizes studies that examined the proportion of con-
trolled patients and changes in clinical control.
In our study, 31.1% of patients had persistently poor 
disease control during follow-up and only a small pro-
portion (16.8%) of patients had persistently good con-
trol. We found that persistently controlled patients were 
Fig. 2 Changes in treatment patterns for COPD at baseline and last visit in persistently controlled and uncontrolled patients
Table 4 Comparisons of  baseline data and  annual changes between  persistently controlled patients and  persistently 
uncontrolled patients during 5 years of follow-up
CAT COPD Assessment Test; HDAS Hospital Anxiety and Depression Scale; FEV1 forced expiratory volume in 1 s
Data is presented as mean (SD) or median (5th–95th percentile)
*Statistically significant differences between persistently uncontrolled and persistently controlled patients (p < 0.05)
  Baseline data Annual changes (/year)
Characteristics Persistently controlled Persistently 
uncontrolled
Persistently controlled Persistently uncontrolled
CAT score 9.6 (5.9) 15.5 (7.8)* 0.0 (− 1.0–1.7) 0.2 (− 2.5–3.0)
HDAS anxiety 10.7 (4.8) 11.1 (4.8) 0.0 (− 1.0–2.0) 0.3 (− 1.0–3.0)
HDAS depression 8.0 (4.6) 9.3 (4.9)* 0.5 (− 0.3–2.3) 0.0 (− 1.6–3.0)
FEV1, %pred 71.2 (20.8) 52.3 (19.9)* 0.3 (− 2.8–3.0) − 0.2 (− 3.4–1.5)
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younger, had less frequent chronic bronchitis, a lower 
degree of airflow obstruction, lower involvement in the 
diffusion test, a better quality of life as evaluated by the 
CAT and a higher level of peripheral eosinophilia. In 
previous studies [9, 10, 20, 21], the presence of chronic 
bronchitis, female sex, lower BMI and a history of prior 
exacerbations were identified as variables that were sig-
nificantly associated with poor control. In addition, poor 
lung function and worse health status were demonstrated 
to be the best predictors of the risk of future exacerba-
tions and were associated with a significant increase 
in the risk of mortality [22]. However, our study found 
that sex, tobacco history, BMI and comorbidities such as 
bronchial asthma or anxiety and depression were simi-
lar in patients, irrespective of longitudinal clinical con-
trol status. These results are similar to those reported 
by Calverley et al. [23], who showed that tobacco history 
and BMI were similar in individuals with frequent exac-
erbations and those who never experienced an exacerba-
tion over the 2  years of follow-up. However, continued 
smoking in patients with COPD has been associated with 
higher disease impact and increased exacerbations [24]. 
In addition, former smokers had a significantly reduced 
risk of death and hospitalization compared to active 
smokers [25]. In our study, the majority of the patients 
maintained their tobacco use status. There were no dif-
ferences in longitudinal clinical control patterns regard-
ing smoking cessation during follow-up.
The use of maintenance respiratory therapy is usually 
thought to reduce risk. However, data reported in the 
ECLIPSE [26] and SPIROMICS [27] cohorts reported 
that patients did shift from high-risk to low-risk groups 
over time, though the reasons for doing so were unclear. 
In any case, adequate therapy seems to improve the ratio 
of infrequent to frequent exacerbators over time [28–30]. 
In our study, triple therapy at baseline was less frequent 
in persistently controlled patients (37%) versus persis-
tently uncontrolled patients (72.2%). At the end of the 
follow-up period, 20% of persistently controlled patients 
had scaled up their treatment, with triple therapy being 
the most frequent therapeutic pattern. On the con-
trary, in persistently uncontrolled patients, 13.3% had 
increased their pharmacological treatment while 15% 
had decreased it, observing a decrease in triple therapy 
and an increase in double bronchodilator therapy. These 
results for the changes in treatment pattern according to 
longitudinal control status provide interesting informa-
tion, showing an increase in triple therapy in persistently 
controlled patients. In our study, not requiring triple 
therapy at baseline and having a better quality of life were 
identified as variables that were significantly associated 
with persistent disease control. A likely explanation why 
patients are given triple therapy to prevent exacerba-
tions is because they are believed to be progressing more 
poorly and are thus more likely to relapse in the future, 
irrespective of any positive effect of their therapy.
A previous publication described control status as a 
marker of increased risk of poor outcomes in the short 
term. According to data reported in the studies by Soler-
Cataluña et  al. [8] and Barrecheguren et  al. [31], con-
trolled patients showed a lower risk of complications, 
with a longer delay until the first combined event, the 
first exacerbation and hospitalization, as well as better 
health status at 1  year of follow-up. However, they did 
not report any significant difference in survival between 
controlled and uncontrolled patients. In the Miravitlles 
et al. [20] study, uncontrolled patient visits resulted in a 
highly significant increased risk of poor outcomes over 
the next 6 months, with an OR of 4.25 for hospitalization 
due to exacerbation compared to controlled patient vis-
its. In addition, it has been reported that control status 
determined by clinical criteria was a better predictor of 
exacerbations compared to CAT criteria (AUC: 0.67 vs 
0.57) [32]. Our analysis showed that although a further 
worsening in CAT and HDAS scores and FEV1 levels was 
observed in persistently uncontrolled patients, there were 
no significant differences in annual changes between per-
sistently controlled and uncontrolled subjects. However, 
we found that persistently controlled patients had a sig-
nificantly lower risk of death than those who were persis-
tently uncontrolled. In our study, there were 94 (24.6%) 
Fig. 3 Kaplan–Meier analysis for all‑cause mortality. Persistently 
controlled patients were associated with a longer survival time than 
persistently uncontrolled patients
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deaths in 5 years of follow-up, a mortality rate similar to 
that of the Spanish PAC-EPOC cohort (3.6 fatal events/
year/100 patients) [33]. Specifically, there were 73 deaths 
in persistently uncontrolled patients and 21 in controlled 
patients. Our analysis further confirmed that subjects 
who died were older, had a greater degree of airway 
obstruction, and had worse health status than those who 
survived. These results are similar to those reported by 
Oga et al [34]. Changes in mortality occur after the first 
year and tend to increase in the second year, which could 
explain why this was not observed in previous studies [8].
Our study extends our understanding of the concept of 
control in COPD and its possible application in clinical 
practice. Previous studies have found that improvement 
in control status in the short term was associated with 
better outcomes, with a reduced frequency of exacerba-
tions and improved health status. Our results show that 
patient control status frequently changes in subsequent 
clinical visits and we observed that there are long-term 
consequences: persistently uncontrolled patients have 
higher mortality. This is the first study to show the impact 
of control status on long-term mortality. This increased 
risk justifies the use of control evaluation as a warning 
sign to foster more careful evaluation of the patients and 
the adoption of therapeutic measures.
This study has several strengths. It included a large 
number of well-characterized patients being treated for 
COPD in “real life” with a long follow-up time, provid-
ing invaluable information on outcomes which is not 
usually available in most pharmacological trials. How-
ever, it is necessary to keep in mind some characteristics 
of the cohort in order to correctly interpret our results. 
The CHAIN cohort was obtained from an observa-
tional study of patients visiting pulmonary clinics and 
not from general medical practice. In fact, patients with 
COPD treated in a specialized clinic have been found 
to have better clinical control [35]. In the Baloira et  al. 
[36] study, patients at the primary care level were more 
poorly controlled. However, our cohort included a large 
population of patients with different degrees of severity 
(16.4% mild, 46% moderate, 26.8% severe and 10.8% very 
severe). Another consideration is that few women were 
included in the cohort and the findings reported in rela-
tion to this must be interpreted with caution. There was 
also a loss of patients during follow-up that could result 
in measurement bias. Regarding the limitations of the 
present study, it is important to consider that the prob-
ability of change in clinical control status will be greater 
for a longer follow-up period. In our analysis, a minimum 
of 1  year of follow-up was established as a criterion to 
define the longitudinal pattern since our objective was to 
explore the differences between persistently controlled 
and uncontrolled classifications and to analyze their 
prognostic implications such as mortality. In this sense, 
it is worth mentioning that in our analysis, there was a 
higher number of exitus in the first year of follow-up: 48 
patients defined as persistently uncontrolled and 13 as 
persistently controlled. In addition, if we establish a mini-
mum of 3 years of follow-up as a criterion, the majority 
of patients (76.8%) would be classified as intermittently 
controlled. Therefore, we defined the longitudinal pattern 
with a minimum of 1 year of follow-up, also keeping in 
mind that this criterion perhaps most closely resembles 
ordinary clinical practice. Another limitation is that this 
was not an interventional study, we could not investigate 
whether a change in treatment could modify control sta-
tus and influence the outcomes. This has to be demon-
strated in future interventional studies.
Conclusions
This is the first study to show the impact of control sta-
tus on long-term mortality. There is important variability 
in clinical control status and only a small proportion of 
patients had persistently good control. The study high-
lights the significantly increased risk of death in uncon-
trolled patients. Consequently, control criteria should 
be incorporated into clinical practice as a simple tool to 
help reassess patients with COPD at each follow-up visit. 
Further studies in other populations should validate our 
results.
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